|Articles|September 16, 2021
Clinscience Digitizes Clinical Research by Investing in EXOM Group
Advertisement
Clinscience, on September 15th signed an investment agreement to acquire 60% of the digital CRO—EXOM Group. Headquartered in Milan, EXOM carries out its activities in the design, supervision, monitoring and management of Clinical Trials based on its own digital eco-system of more than 20 applications unified in the multi-modular platform Genius Suite.
EXOM Group's proprietary Genius Suite system will allow Clinscience to continue its digital transformation and conduct Clinical Trials with a focus on the needs of both Investigators and Patients and ultimately Sponsors.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work
2
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
3
ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment
4
Breaking the Efficacy Ceiling in IBD and Beyond
5